CRANBURY, N.J., April 24 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30, 2008, at 2:20 p.m. EDT, at the Ritz-Carlton in Key Biscayne, Florida.
The presentation will be webcast live and may be accessed by visiting Amicus' website at http://www.amicustherapeutics.com. A replay of the webcast will also be available on the Company's website for 30 days until May 30, 2008.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel,
oral therapeutics known as pharmacological chaperones for the treatment of
a range of human genetic diseases. Pharmacological chaperone technology
involves the use of small molecules that selectively bind to and stabilize
proteins in cells, leading to improved protein folding and trafficking, and
increased activity. Amicus is initially targeting lysosomal storage
disorders, which are severe, chronic genetic diseases with unmet medical
needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the
treatment of Fabry disease and is conducting Phase 2 clinical trials of
Plicera(TM) for the treatment of Gaucher disease. The Company recently
completed Phase I clinical trials of AT2220 for the treatment of Pompe
John Quirk Cory Tromblee
Porter Novelli Life Sciences Porter Novelli Life Sciences
(212) 601-8296 (617) 897-8294
|SOURCE Amicus Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved